Rytelo
What Rytelo is used for
Treatment of transfusion-dependent anaemia in adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Rytelo
- Active substance
- imetelstat
- Disease area
- Anemia; Myelodysplastic Syndromes
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX80
- Marketing authorisation holder
- Geron Netherlands B.V.
- Authorised in the EU since
- 2025
Official information
In the USA
Same active substance: Rytelo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rytelo used for?
Treatment of transfusion-dependent anaemia in adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
What is the active substance in Rytelo?
Rytelo contains imetelstat.
Who makes Rytelo?
The EU marketing authorisation holder is Geron Netherlands B.V..
Is Rytelo an orphan medicine?
Yes. Rytelo is designated an orphan medicine in the EU, for a rare disease (Anemia; Myelodysplastic Syndromes).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU